Topic of The Week: Covid-19 Variants We offer an equity analysis subscription service with; nightly email, SMS alerts, in-depth reports, and more. Try us out with a free trial and cancel anytime … [Read more...] about The Emergence of Covid-19 Variants
BCX9930: Priceless
We offer an equity analysis subscription service with; nightly email, sms alerts, in depth reports and more. Try us out with a free trial and cancel anytime to see if we're a good fit for your needs! … [Read more...] about BCX9930: Priceless
After a Transformational Year in 2020 Dario Health (Nasdaq: DRIO) is Poised for Significant and Sustained Growth
Price as of 3/19/21: $19.70Market Cap: $300MRating: BuyEntry= $18.15-$206-12 month Price Target = $40-50 (+100-150%+ upside potential)Team Contact: info@msmoneymoves.com Our Thesis Early in … [Read more...] about After a Transformational Year in 2020 Dario Health (Nasdaq: DRIO) is Poised for Significant and Sustained Growth
Dario Health (Nasdaq: DRIO) 2020 Earnings Price Performance Study
Below you will find the historical performance of DRIO surrounding earnings. This is intended to provide investors with data driven insights into previous performance. For our latest research on DRIO, … [Read more...] about Dario Health (Nasdaq: DRIO) 2020 Earnings Price Performance Study
KNSA Report
New core position *for a copy of our disclaimer click here. This is our opinion and should not serve as advice Kiniksa Pharmaceuticals (Nasdaq: KNSA) Buy Zone = $18-21 PT= $30-40 (by or around … [Read more...] about KNSA Report
GNMK Coverage Update
GenMark Diagnostics (Nasdaq: GNMK) Coverage Update 2/7/21 Outlook: Bullish PT = $20 (0-24 weeks) About GNMK A commercial-stage medical-diagnostic company marketing its proprietary eSensor … [Read more...] about GNMK Coverage Update
BioCryst Pharmaceuticals (Nasdaq: BCRX): This Is Big
For a free trial of our premium service, click here.This is big.Since presenting our initial research on BioCryst Pharmaceuticals (Nasdaq: BCRX) and its embarrassment of riches on 8/4/20, the company … [Read more...] about BioCryst Pharmaceuticals (Nasdaq: BCRX): This Is Big
DRIO Q1-Q3, 2020 Financial Breakdown
1Q20 2Q20 3Q20 Cash position $15.8M $13.2M $37M Revenue $1.6M * $1.79M * $2.04M * ▲QoQ rev (7.3%) 7.2% 14.2% ▲ YoY rev (25.6%) ** 8.2% 9.3% Gross … [Read more...] about DRIO Q1-Q3, 2020 Financial Breakdown
Kintara Therapeutics (Nasdaq: KTRA) Remains Underappreciated Despite an Upbeat GBM Data Update at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting
Kintara Therapeutics (Nasdaq: KTRA) is a newly-formed, late-stage, oncology-focused pharmaceutical company resulting from the strategic acquisition of Adgero Biopharma by DelMar … [Read more...] about Kintara Therapeutics (Nasdaq: KTRA) Remains Underappreciated Despite an Upbeat GBM Data Update at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting
KTRA/DMPI SNO Historical Performance
Below is historical data of how KTRA (formally DMPI) performed after presenting at Society for Neural Oncology (SNO). KTRA is set to present data at (SNO) which is anticipated November 19th-22. The … [Read more...] about KTRA/DMPI SNO Historical Performance
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish